Citing ‘dangerous deals,’ lawmakers propose China restrictionsnews2026-06-02T12:00:58+00:00June 2nd, 2026|Endpoints News|
After being ditched by Candid, Rallybio finds Avenzo to take its Nasdaq listingnews2026-06-01T14:11:13+00:00June 1st, 2026|Endpoints News|
Servier signs $1.55B upfront deal for Edgewise’s muscular dystrophy assetsnews2026-06-01T12:31:49+00:00June 1st, 2026|Endpoints News|
Lilly licenses GLP-2 asset from Korean biotech Hanmi for $75M upfrontnews2026-06-01T10:43:21+00:00June 1st, 2026|Endpoints News|
Pfizer strikes Innovent deal worth up to $10.5B for a dozen cancer programsnews2026-05-29T10:50:55+00:00May 29th, 2026|Endpoints News|
Apogee secures Blackstone capital to move Dupixent rival into Phase 3news2026-05-27T15:07:51+00:00May 27th, 2026|Endpoints News|
WuXi Bio signs deal to manufacture Viridian’s thyroid eye disease drugnews2026-05-27T13:55:31+00:00May 27th, 2026|Endpoints News|
Lilly to acquire three vaccine biotechs for up to $3.8Bnews2026-05-26T11:20:08+00:00May 26th, 2026|Endpoints News|
GOP lawmaker asks Trump administration to curb China biotech dealsnews2026-05-22T17:50:05+00:00May 22nd, 2026|Endpoints News|
Incyte signs AI deals with Genesis Molecular AI, Edison Scientificnews2026-05-21T14:22:03+00:00May 21st, 2026|Endpoints News|
